PepJunkie Home of the Peptonauts
More

Peptide Atlas · Peptide

Davunetide

Davunetide (NAP, AL-108) is an intranasal peptide that stabilized microtubules and reduced tau phosphorylation in preclinical studies; in a 52-week phase 2/3 trial in 313 people with progressive supranuclear palsy it did not differ from placebo on either primary measure.

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

    • emerging
      Claim: Davunetide in schizophrenia: no cognitive effect, functional capacity improved (RCT, n=63) standing
    • resolved

    Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.

    Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, Barch DS, Ball MP, Robinson J, Marder SR

    pmid 22169248

    • established
      Claim: Davunetide was not effective in progressive supranuclear palsy (phase 2/3 RCT) standing
    • resolved

    Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.

    Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Höglinger GU, Koestler M, Jack CR, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH, AL-108-231 Investigators

    pmid 24873720

A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.